Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full yea ...

Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, and Vicore Pharma, a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 ...

Infertility is defined as the inability to be pregnant within one year of unprotected intercourse. It has become not only a ...

S L E is a chronic multisystem autoimmune disease in which cardiovascular disease is a leading cause of mortality, with a ...

Louisiana State Employees Retirement System boosted its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.4% during the 4th quarter, according to the company ...

为解决肾素合成、作用及肾素抑制保护肾功能机制不明等问题，UND Life Sciences 等机构研究人员开展肾素与花生四烯酸（AA）及其代谢产物关系研究。发现 AA 可调节肾素相关机制，为防治高血压、保护肾功能提供新思路，值得一读。

Hypertension in pregnancy contributes substantially to maternal morbidity and mortality, persistent hypertension, and rehospitalization. Hypertensive disorders of pregnancy are also associated with a ...

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

FSGS is characterized by proteinuria, where protein leaks into the urine due to a breakdown of the normal filtration mechanism in the kidney ... Do not coadminister FILSPARI with angiotensin receptor ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...

Even drugs designed to treat the same condition may target different biological mechanisms, which might explain the varying results. For example, some blood pressure medications - such as ACE ...

Even drugs designed to treat the same condition may target different biological mechanisms, which might explain the varying results. For example, some blood pressure medications – such as ACE ...